Drug Development Navigation Platform

CMC requirements don't slow programs down.
Not knowing them in advance does.

CMC Drug Development connects Chemistry, Manufacturing and Controls expectations, phase-graded regulatory requirements, and program timelines for Small Molecule, Cell Therapy, and Gene Therapy into one structured navigation system.

Know the requirements. Plan the timeline. Navigate the gate. File with confidence.

Discover
Design
Develop
Manufacture
Register
Commercialize
77
CTD Sections
2,100+
Requirements Mapped
11
Stage Gates
3
Modalities
More below

The Common CMC Problem

Most CMC deficiencies are not caused by bad science. They are caused by requirements that were not known, planned for, or completed at the right phase.

Phase 2 starts. A regulatory review reveals that key characterization studies, control strategy elements, or stability data expected by the agency were never planned — because no one mapped the requirements to the timeline in advance.

CMC Drug Development replaces reactive discovery of regulatory expectations with a structured, phase-graded navigation system — mapped to CTD sections, modality, dosage form, and development stage before the work begins.

Unplanned CMC work

Studies, methods, and packages that should have been scoped at IND appear as surprises at Phase 2 or Phase 3.

Filing delays

Missing or incomplete CTD sections discovered during submission assembly push NDA or BLA timelines by months.

Agency deficiencies

CMC deficiency letters require costly response cycles, additional studies, and extended review timelines.

Patient access delays

Every CMC gap that surfaces late translates directly into delayed product availability for the patients who need it.

Three Integrated Tools

From CTD section requirements to full development timeline — in one platform.

CMC Drug Development gives development teams, CMC leads, and regulatory professionals a connected navigation system that spans the full lifecycle — from early molecule selection through commercial readiness.

Tool 1 — CMC Navigator

Phase-graded CTD requirements, searchable and filterable by modality, dosage form, and phase.

Navigate all 77 CTD Module 3 sections with phase expectations (IND → Phase 2 → Phase 3 → NDA/BLA), regulatory watchouts, and ICH/FDA/EMA reference citations — filtered to your molecule and dosage form.

  • 2,100+ requirements mapped across 3.2.S, 3.2.P, and 3.2.A sections
  • Filter by modality: Small Molecule, Cell Therapy, Gene Therapy, Biologics
  • Phase-required tags: Expected · Recommended · As-needed
  • Regulatory citations: ICH Q guidelines, FDA/EMA guidance, USP
Open CMC Navigator →
CTD Module 3 Coverage
3.2.S — Drug Substance
3.2.S.1General Information
3.2.S.2Manufacture (DS)
3.2.S.3Characterisation
3.2.S.4Control of DS
3.2.S.5Reference Standards
3.2.S.6Container Closure
3.2.S.7Stability (DS)
3.2.P — Drug Product
3.2.P.1Description & Composition
3.2.P.2Pharma Development
3.2.P.3Manufacture (DP)
3.2.P.4Control of Excipients
3.2.P.5Control of DP
3.2.P.6Reference Standards
3.2.P.7Container Closure
3.2.P.8Stability (DP)
3.2.A · 3.2.R · 3.3
3.2.AAppendices
3.2.RRegional Info
3.3Literature References
Tool 2 — Drug Development Timelines

Aggressive but achievable timelines — for programs that plan CMC from day one.

Modality-specific timelines showing your target vs. industry average at every phase — so you know exactly where structured CMC planning compresses the calendar.

  • ~8–9 yr structured program vs. 10–15 yr industry average
  • Phase-level bars: target vs. industry avg side by side
  • Small Molecule, Cell Therapy, and Gene Therapy timelines
  • 6 phases · 20 SM stages · 16 Cell/Gene stages
View Development Timelines →
Structured Programvs. Industry Avg
Discovery
18 mo
vs. 18–24 mo avg
Pre-Clinical
24 mo
vs. 30–36 mo avg
Ph1 Clinical
14–18 mo
vs. ~25 mo avg
Ph2 Clinical
24 mo
vs. ~43 mo avg
Ph3 Clinical
30 mo
vs. ~40 mo avg
NDA/BLA Review
6–10 mo
PDUFA goal
~8–9 yr totalvs. 10–15 yr industry average
Tool 3 — Stage Gate Framework

11 universal gates with decision criteria, SME readiness scoring, and cross-functional sign-off.

From Opportunity/Portfolio (G0) through Lifecycle (G10) — each gate defines the decision question, core evidence required, Go/Conditional-Go/No-Go framework, and required signatories. Internal SME readiness assessment → gate review → decision → formal sign-off.

  • 686 SM gate criteria · 492 Cell Therapy · 489 Gene Therapy
  • Functional ownership per criterion: CMC, QA/REG, TOX, CLIN OPS, R&D
  • Power BI-ready gate tracker included
  • Auditable gate record with formal sign-off
Explore the Gate Framework →
11 Universal Stage Gates
G0
Opportunity
G1
Target Concept
G2
Dev Candidate
G3
IND Enabling
G4
IND Cleared
G5
Phase 1
G6
EOP2
G7
Pivotal
G8
Submission
G9
Approval
G10
Lifecycle

Three Modalities. One Platform.

Requirements, timelines, and gate checklists — mapped to your molecule type from day one.

Small molecule, cell therapy, and gene therapy development paths are structurally different. CMC Drug Development treats them that way.

Small Molecule

Conventional & complex synthetics

From target identification through NDA approval. Pre-formulation, formulation development, PK/PD, full ICH toxicology, GMP DS/DP manufacturing, and clinical development. 572 cross-mapped tasks.

20 stages6 phases~9 yrNDA pathway
View timeline →
Cell Therapy

Autologous & allogeneic cell products

Construct selection, cell collection & donor eligibility, cell processing, analytical method development, GMP manufacturing, IND through BLA — with modality-specific CMC expectations for living cell products.

16 stages~8 yrBLA pathway492 criteria
View timeline →
Gene Therapy

Viral vectors & gene editing constructs

Target strategy, modality decision gate, lead vector selection, production process, GLP biodistribution, GMP vector manufacturing, IND through BLA — with gene therapy-specific CMC expectations.

16 stages~9 yrBLA pathway489 criteria
View timeline →

Request Your Program Plan

Submit your program information. Receive the stage-gate schedule and modality-specific gate checklist.

Provide your program details below and we will return a modality-specific stage-gate schedule and gate checklist tailored to your development pathway.

Program Information Request

All fields help us return the most relevant program plan for your development stage and molecule type.

You will receive the modality-specific stage-gate schedule and gate checklist. No spam.

Request received — thank you.

We will send your program plan to the email provided within 1–2 business days.

Part of the I²nnovate Ecosystem

CMC Drug Development is the regulatory navigation layer of the I²nnovate platform.

Sustainable High Performance

Aligned Strategy · Actionable Insights · Disciplined Execution · Measurable Results

01

I²nnovate

Operating Model Platform

Aligns strategy, people, process, systems, performance, and leadership cadence into one system for sustainable high performance.

i2nnovate.com →
Delivers
  • Strategic Alignment
  • Leadership Cadence
  • Organizational Accountability
  • Continuous Improvement
02

The Actionable Insights

Performance Intelligence Layer

Integrated KPI dashboards that convert data into clarity, decisions, ownership, and action across the organization.

theactionableinsights.com →
Delivers
  • Executive Visibility
  • KPI Architecture & Governance
  • Insight-to-Action Workflow
  • Faster, Better Decisions
03

PMO Performance

Execution Governance Layer

Program and governance framework that prioritizes, manages, and delivers initiatives for measurable and sustainable business results.

pmoperformance.com →
Delivers
  • Portfolio Prioritization
  • Execution Governance
  • Risk & Issue Management
  • Benefits Realization
04

CMC Drug Development YOU ARE HERE

Regulatory Navigation Layer

Phase-graded CMC requirements, modality-specific program timelines, and stage-gate frameworks — from IND through approval across Small Molecule, Cell Therapy, and Gene Therapy.

Delivers
  • CTD Section Navigation
  • Phase-Graded Requirements
  • Program Timelines (SM / Cell / Gene)
  • Stage Gate Framework
05

CDMO Performance

External Manufacturing Layer

Stage-gated CDMO management platform with PSQDC scorecards and weighted performance index for sponsor-side oversight of external manufacturing partnerships.

cdmoperformance.com →
Delivers
  • CDMO Selection Governance
  • PSQDC Scorecards
  • Tech Transfer Stage Gates
  • Inspection Readiness

Ready to Navigate CMC?

Know the requirements. Plan the timeline. File the right package.

Start with the CMC Navigator to explore phase-graded requirements for your CTD sections, explore the development timelines for your modality, or request your modality-specific program plan and gate checklist.